ECHS1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the ECHS1 gene has been disrupted in the SK-HEP-1 human hepatocellular carcinoma cell line. This gene-edited model provides a loss-of-function system for studying the role of mitochondrial enoyl-CoA hydratase in cancer metabolism and related mitochondrial disorders. The polyclonal knockout format ensures a heterogeneous population of edited cells, enabling robust analysis of functional consequences without the selective pressures of clonal isolation, making it suitable for bulk assays that capture population-level metabolic responses.
The host cell line, SK-HEP-1, was established from the ascitic fluid of a patient with liver adenocarcinoma and exhibits an epithelial morphology characteristic of malignant hepatic cells. SK-HEP-1 cells are widely employed in cancer biology studies, particularly for investigations into hepatocellular carcinoma pathophysiology, metabolic reprogramming, and drug metabolism. Their origin and well-documented phenotype make them a relevant model for exploring the intersection between oncogenic transformation and mitochondrial energy metabolism.
ECHS1 encodes a mitochondrial enoyl-CoA hydratase that catalyzes the second step of fatty acid ??-oxidation, converting enoyl-CoA esters to 3-hydroxyacyl-CoA intermediates. This enzymatic reaction is essential for the sequential degradation of long-chain fatty acids, ultimately fueling the tricarboxylic acid (TCA) cycle and ATP production. ECHS1 is transcriptionally activated by PPAR?? and PGC-1?? in response to fatty acid ligands, integrating lipid metabolism with cellular energy status. Within the ??-oxidation spiral, ECHS1 functions downstream of acyl-CoA dehydrogenase and upstream of 3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA thiolase, physically interacting with Coenzyme A and enoyl-CoA substrates. The enzyme is also implicated in branched-chain amino acid catabolism, linking it to broader metabolic networks. Disruption of ECHS1 in SK-HEP-1 cells leads to accumulation of enoyl-CoA esters, impaired acetyl-CoA generation, and attenuation of oxidative phosphorylation, thereby activating compensatory signaling pathways such as AMPK and altering mitochondrial morphology.
In the context of hepatocellular carcinoma, ECHS1 knockout creates a powerful model for studying metabolic reprogramming under the influence of oncogenic signaling. The reliance of many cancer cells on fatty acid oxidation for energy and biosynthetic precursors makes ECHS1 disruption a valuable tool to probe dependencies on mitochondrial respiration. The resulting metabolic stress??characterized by reduced ATP output and potential reductive stress??may induce adaptive shifts toward glycolysis, activate reactive oxygen species (ROS) signaling, or trigger apoptosis. Consequently, this model is highly relevant for research on cancer metabolism, mitochondrial disease mechanisms (including Leigh syndrome), and the evaluation of therapeutic strategies targeting metabolic vulnerabilities in liver tumors.
Typical applications of ECHS1 Knockout SK-HEP-1 Polyclonal Cells span metabolic rewiring assessments, mitochondrial function characterizations, and drug-screening studies. Researchers routinely employ Seahorse mitochondrial stress tests to measure oxygen consumption rates, complementary fatty acid oxidation assays, and ATP luminescence assays to quantify energy deficits. Western blotting and RT-qPCR are used to validate knockout status and monitor changes in key metabolic regulators, while metabolomics and ROS detection assays provide deeper insights into pathway perturbations. Additional cell viability and annexin V apoptosis assays facilitate evaluation of phenotypic consequences under various culture conditions or drug treatments, advancing discovery in the fields of cancer biology and mitochondrial pathobiology. For further information or to discuss custom applications, please contact Ascent Research.
